All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.
Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally ...
Celgene announced that its drug, Revlimid, gained FDA approval for the treatment of newly diagnosed multiple myeloma. Celgene announced on Feb. 18, 2015 that its cancer drug Revlimid (lenalidomide) ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings. The MajesTEC ...
Rafael Fonseca, MD, reviews data on rescue isatuximab from the ASH 2021 annual meeting and discusses use of best therapies up front. Rafael Fonseca, MD: A study was presented in which isatuximab ...
Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly ...
Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Background: LEN + DEX (Rd) is approved for pts with ...
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback